Brief introduction：The first beta blocker which completed the Quality Consistency Evaluationpassed in China. Indicated to lower high blood pressure helps prevent strokes, heart attacks, and kidney problems.
Brief introduction：It is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5-10 days.
Brief introduction：Deemed to have completed the Quality Consistency Evaluation; It's used for treatment of following: prevent Atherothrombosis; patients with acute myocardial infarction(AMI), ischemic stroke, peripheral arterial disease(PAD) and acute coronary syndrome(ACS).
Add: No.8, Xiyuan Ave., Hi-tech District, Chengdu, 611731, China
This website does not publish the product information of narcotic drugs, psychotropic drugs, toxic drugs for medical use, radioactive drugs, drug rehabilitation drugs and preparations of medical institutions.|
Copyright ? 成都苑東生物制藥股份有限公司 ALL Rights Reserved互聯網藥品信息服務資格證編號：(川)-非經營性-2021-0036